Logo Image
|Articles|May 3, 2010

United BioSource Acquires Abt Bio-Pharma Solutions

United BioSource Corporation (UBC)

announced the acquisition of

Abt Bio-Pharma Solutions, Inc.

(ABS), a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries.

The acquisition of ABS is part of UBC’s ongoing strategy to build a “best in class” portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies.  With this acquisition UBC further expands its team of senior experts in comparative effectiveness and comparative value; increases its registry and observational study practices; and reinforces its commercial strategy and market access capabilities.

“UBC is an ideal home for ABS,” said Abt Associates Chief Executive Officer Kathleen Flanagan. “We are gratified to see our colleagues join an organization that shares our values.  At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support the development and commercialization of their products.”

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more